The estimated Net Worth of William T. Burkoth is at least $106 Thousand dollars as of 21 May 2019. William Burkoth owns over 6,145 units of NovoCure Ltd stock worth over $105,878 and over the last 9 years William sold NVCR stock worth over $0.
William has made over 1 trades of the NovoCure Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently William exercised 6,145 units of NVCR stock worth $300,306 on 21 May 2019.
The largest trade William's ever made was exercising 6,145 units of NovoCure Ltd stock on 21 May 2019 worth over $300,306. On average, William trades about 1,536 units every 0 days since 2016. As of 21 May 2019 William still owns at least 6,145 units of NovoCure Ltd stock.
You can see the complete history of William Burkoth stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PKWY, SUITE 300, MALVERN, PA, 19355.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: